Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Germany”

Extension Study for the Port Delivery System With Ranibizumab (Portal)Recruiting
NCT03683251Phase 3Updated Jul 31, 2026
Sponsor: Hoffmann-La Roche
Neovascular Age-Related Macular Degeneration
United States, Argentina, Australia, Austria, Belgium +10 more
Establishment and Evaluation of Standardized Clinical, Biological and Imaging Parameters to Assess the Response of LDRT in Heel Spur With Plantar FasciitisRecruiting
NCT06969820N/AUpdated Jul 31, 2026
Sponsor: University of Erlangen-Nürnberg Medical School
Calcaneal Spur
Germany
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical PracticeActive Not Recruiting
NCT05049798N/AUpdated Jul 31, 2026
Sponsor: Janssen Pharmaceutica N.V., Belgium
Arthritis, Psoriatic
Argentina, Australia, Austria, Belgium, Canada +15 more
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.Recruiting
NCT06991114Phase 2Updated Jul 31, 2026
Sponsor: Artiva Biotherapeutics, Inc.
Refractory Rheumatoid Arthritis (RA) · Idiopathic Inflammatory Myopathies (IIMs) · Systemic Sclerosis (SSc) · Rheumatoid Arthritis (RA
United States, Brazil, Bulgaria, France, Germany +6 more
A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global RegistryRecruiting
NCT07194070N/AUpdated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Hemolytic Disease of the Fetus and Newborn
United States, Australia, Belgium, Brazil, Germany +3 more
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received ChemotherapyRecruiting
NCT06750094Phase 3Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Colorectal Neoplasms
United States, Australia, Belgium, Brazil, China +21 more
A Study of DaratumumabActive Not Recruiting
NCT05438043Phase 3Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Multiple Myeloma
United States, Belgium, Brazil, China, Czechia +12 more
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic ArthritisCompleted
NCT05083182Phase 3Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Arthritis, Juvenile
United States, Argentina, Denmark, France, Germany +5 more
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruiting
NCT07518186Phase 3Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Multiple Myeloma
United States, Australia, China, France, Germany +10 more
Study of Erdafitinib Intravesical Delivery System for Localized Bladder CancerActive Not Recruiting
NCT05316155Phase 1, Phase 2Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Non-Muscle Invasive Bladder Neoplasms
United States, Canada, Germany, Israel, Japan +3 more
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)Recruiting
NCT07164443Phase 3Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Metastatic Castration-resistant Prostate Neoplasms
United States, Australia, Belgium, Brazil, Canada +12 more
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Recruiting
NCT05327114Phase 2, Phase 3Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
United States, Argentina, Australia, Canada, China +14 more
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaRecruiting
NCT07011719Phase 3Updated Jul 31, 2026
Sponsor: Arcus Biosciences, Inc.
Metastatic Clear Cell Renal Cell Carcinoma · Advanced Clear Cell Renal Cell Carcinoma
United States, Argentina, Australia, Canada, Czechia +11 more
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the BladderActive Not Recruiting
NCT04658862Phase 3Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Urinary Bladder Neoplasms
United States, Argentina, Australia, Austria, Belgium +20 more
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer TherapiesActive Not Recruiting
NCT03888105Phase 2Updated Jul 31, 2026
Sponsor: Regeneron Pharmaceuticals
B-cell Non-Hodgkin Lymphoma (B-NHL)
United States, Australia, Canada, China, France +9 more
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis SuppurativaActive Not Recruiting
NCT06921850Phase 3Updated Jul 31, 2026
Sponsor: UCB Biopharma SRL
Hidradenitis Suppurativa
United States, Germany, Poland
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical CystectomyActive Not Recruiting
NCT04640623Phase 2Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Urinary Bladder Neoplasms
United States, Australia, Belgium, Canada, France +11 more
A Long-term Extension Study of PCI-32765 (Ibrutinib)Recruiting
NCT01804686Phase 3Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Mantle Cell Lymphoma · Follicular Lymphoma
United States, Argentina, Australia, Belgium, Brazil +25 more
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic ArthritisRecruiting
NCT07321873Phase 2Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Arthritis, Psoriatic
United States, China, Czechia, Germany, Hungary +3 more
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus NephritisActive Not Recruiting
NCT05138133Phase 3Updated Jul 31, 2026
Sponsor: AstraZeneca
Lupus Nephritis
United States, Argentina, Belgium, Brazil, Bulgaria +19 more
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)Recruiting
NCT07252232Phase 3Updated Jul 31, 2026
Sponsor: Revolution Medicines, Inc.
Pancreatic Cancer · PDAC · PDAC - Pancreatic Ductal Adenocarcinoma · Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
United States, France, Germany, Italy, Japan +4 more
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCCRecruiting
NCT04892173Phase 3Updated Jul 31, 2026
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
Carcinoma, Squamous Cell
United States, Austria, Belgium, Brazil, Bulgaria +22 more
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic AnemiaActive Not Recruiting
NCT04119050Phase 2, Phase 3Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Warm Autoimmune Hemolytic Anemia
United States, Brazil, China, Czechia, Egypt +14 more
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical TrialsRecruiting
NCT06285318N/AUpdated Jul 31, 2026
Sponsor: Janssen-Cilag Ltd.
Relapsed/Refractory Multiple Myeloma (RRMM)
Denmark, France, Germany, Greece, Ireland +6 more
Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot PhaseRecruiting
NCT07640542EARLY_Phase 1Updated Jul 31, 2026
Sponsor: MODAG GmbH
Parkinson Disease (PD) · MSA - Multiple System Atrophy · Healthy Adult Participants
Germany

Previous page Next page